Cite
1275P Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group
MLA
R. Blanco, et al. “1275P Extended Follow-up of DURVAST Trial: A Phase II Study Evaluating Durvalumab Treatment in HIV-1-Infected Patients with Solid Tumours by the Spanish Lung Cancer Group.” Annals of Oncology, vol. 31, Sept. 2020, p. S825. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........c2273a4d7adecb3ae57d7eb1f4c27fde&authtype=sso&custid=ns315887.
APA
R. Blanco, Judith Dalmau, Javier Martinez-Picado, M. González Cao, Teresa Moran, M. Provencio Pulla, J. De Castro Carpeno, Ana Drozdowskyj, R. Rosell Costa, R. Bernabé, Bonaventura Clotet, Julia G. Prado, O.J. Juan Vidal, Julià Blanco, Javier Garcia-Corbacho, M.A. Molina-Vila, B. Massuti Sureda, & Andreas Meyerhans. (2020). 1275P Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group. Annals of Oncology, 31, S825.
Chicago
R. Blanco, Judith Dalmau, Javier Martinez-Picado, M. González Cao, Teresa Moran, M. Provencio Pulla, J. De Castro Carpeno, et al. 2020. “1275P Extended Follow-up of DURVAST Trial: A Phase II Study Evaluating Durvalumab Treatment in HIV-1-Infected Patients with Solid Tumours by the Spanish Lung Cancer Group.” Annals of Oncology 31 (September): S825. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........c2273a4d7adecb3ae57d7eb1f4c27fde&authtype=sso&custid=ns315887.